Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.

Exclusion Criteria

• •Evidence of acute rejection episode within the past three months
• •Pt not Africa-American
• •Recipients of organ transplants other than kidney
• •Known to be HIV positive at transplant
• •Pt with recurrent focal segmental glomerulosclerosis (FSGS)
• •Pt with any severe medical condition (including infection) requiring acute or chronic treatment
• •Pt with a positive DSA
• •Pt with a positive BK virus results
• •GFR \< 25 ml/min measured by MDRD4 as SOC within last 30 days
• •Patients with AST, ALT, total bilirubin \> 2.5 x ULN or evidence of severe liver disease
• •Pt with WBC \< to 2000/mm3 or ANC \< to 1500 mm3 with PLT \< 75,000/mm3 or HGB \< 8 g/dl
• •Pt with mental or physical conditions or known non-adherence
• •Presence of intractable immunosuppressant complications of side effects resulting in dose adjustment of tacrolimus
• •Exposed to investigational therapy within 30 days prior to enrollment
• •No anticipated changes in the immunosuppressive regimen, other than those specified by the study protocol
• •Pt with severe diabetic gastroparesis or other severe GI disturbances
• •Pt who have underwent gastric banding or gastric bypass at any time pre or post-transplant
• •Pregnant or nursing (lactating) women, or planning to become pregnant
• •Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant who are unwilling to use a defined SOC of method